Clinical Trials

Please Contact Dr. Theodore Friedmann with questions regarding this list: 858-534-4268.

PI

Disease Target

Study Name

Adams S. Fleisher

Alzheimer's Disease

A Phase I Study to Assess the Safety and Tolerability of CERE-110 [Adeno-Associated Virus (AAV)-based, Vector-Mediated Delivery of Beta-Nerve Growth Factor (NGF)] in Subjects with Mild to Moderate Alzheimer’s Disease

Bary Greenberg

Cardiac Disease

Phase I Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID Trial)

Ehtisham Mahmud

Angina Pectoris

AWARE: Angiogenesis in Women with Angina Pectoris Who Are Not Candidates for Revascularization Cardium Therapeutics Protocol No. CT-3-001

Frederick E. Millard

Renal Adenocarcinoma

An International, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate whether TroVax®, Added to First-Line Standard Of Care Therapy, Prolongs the Survival of Patients with Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma (Protocol No. TV3/001/06)

Gerit D Mulder

Diabetic Ulcers

A Long-Term (Year 15) Follow-Up Study of Subjects who were Previously Enrolled in Tissue Repair Company-Sponsored Clinical Trials Using GAM501. (Formerly: A Dose Escalating Phase 1 Study of AdPDGF-B/Collagen (GAM501) in the Treatment of Diabetic Ulcers of the Lower Extremity.)

Gregory A Daniels

Metastatic Melanoma

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma Sponsor [Protocol LX01- 315]

Gregory A Daniels

Melanoma

A Phase 2, Open-Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects with Stage III Melanoma

Gregory A Daniels

Melanoma

A Phase I, Open Label, Dose-Escalation Study of Intratumoral Injection of Adenovirus-Cd154 (Ad-ISF35) in Patients with Unresectable Melanoma or Squamous Cell Carcinoma

H Kirk Hammond



Adenyl cyclase type Vl

Januario Castro

Lymphocytic Leukemia

A PHASE Ib/II STUDY OF REPEAT INTRANODAL INJECTIONS OF ADENOVIRUS-CD154 (Ad-ISF35) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA

Januario Castro

Lymphocytic Leukemia

A Phase Ib Study of Repeated Doses of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Combination with Fludarabine, Cyclophosphamide and Rituximab (FCR) in Subjects with Chronic Lymphocytic Leukemia (CLL)

Lyudmila A. Bazhenova

Lung Cancer

Phase III Prospective, Randomized, Double-blind, Registration Study of Lucanix™ (belagenpumatucel-L) vs. Best Supportive Care as Frontline, Adjuvant Therapy for Stages III/IV Non-small Cell Lung Cancer (Protocol No: NR001-03)

Robert Weisman

Squamous Cell Carcinoma

A Phase III, Multi-Center, Open Label, Randomized, Study to Compare the Overall Survival and Safety of Bi-Weekly Intra-Tumoral Administration of INGN 201 (Ad5CMV-p53) Versus Weekly Methotrexate in 240 Patients with Refractory Squamous Cell Carcinoma of th

Susan J. Little

HIV-1 Vaccine

A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Antiretroviral Effect of Immunization with the MRK Ad5 Hiv-1 Gag Vaccine in Hiv-1 Infected Individuals Who Interrupt Antiretroviral Drug Therapy

Susan J. Little

HIV-1 Vaccine

ACTG A5187. A Phase I/II Clinical Trial to Evaluate the Safety and Immuno-Genicity of the HIV-1 DNA Vaccine VRC-HIVDNAA009-00VP (Gag-Pol-Nef-Multiclade Env) in HIV-1 Infected Subjects Treated during Accute Infection [Version 1.0]

Susan J.Little

HIV-1

AIN504/ACTGA5218: A Randomized Study of Therapeutic Immunization and Treatment Interruption among Subjects Who Began Potent Antiretroviral Therapy Within 16 Days of Diagnosis of Acute or Recent HIV Infection.

Tony R Reid

Esophageal Cancer

GV-001.005: Phase II, Multi-Center, Single Arm Evaluation of Preoperative Chemoradiation Plus TNFerade Biologic (ADgvEGR.TNF.11D) Prior to Esophagectomy for Locally Advanced Resectable Esophageal Cancer.

Tony R Reid

Colorectal Adenocarcinoma

CT 1030: A Phase I/II, Open-Label Study (with a Sequential Dose Escalation Stage Followed by an Expansion of a Selected Dose Cohort), to Evaluate the Safety and Anti-Tumor Effects of NV1020, Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-Line Chemotherapy, in Patients with Colorectal Adenocarcinoma Metastic to the Liver.

Tony R Reid

Melanoma

OncoVEXGM-CSF/002/03: A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX GM-CSF in Patients with Inoperable Malignant Melanoma.

Tony R Reid

Melanoma

A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus plus GM-CSF) Administered by Intratumoral Injection in Patients with Unresectable Stage 3 or Stage 4Malignant Melanoma (Protocol No. JX594-IT-MEL005)

Tony R Reid

Hepatocellular Carcinoma

A Phase II-a, Open-Label, Randomized Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus plus GM-CSF) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma (Protocol No.: JX594-IT-HEP007)

Tony R Reid

Pancreatic Cancer

GV - 001.004: A Randomized, Phase II/III, Study of TNFerade Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer.

Tony R Reid

Pancreatic Cancer

A Phase 2 Double-Blind, Placebo Controlled, Multi-Center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae   Expressing Mutant Ras Protein Combined with a Gemcitabine Regimen Versus a Gemcitabine Regimen with Placebo, in Patients with Post-Resection R0/R1 Pancreatic Cancer with Tumor Sequence Confirmation of Ras Mutations.